Skip to content
Open in App
Summit Therapeutics PLC logo

Summit Therapeutics PLC

web2

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and c...

Symbol · SMMT
Company profile

About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: SMMT
Expert coverage

1 expert evaluated Summit Therapeutics PLC.

Orbitrum research

Experts evaluating Summit Therapeutics PLC

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment